Nitrilotriacetic Acid

Nitrilotriacetic Acid

SCHEMBL244499

O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].O=C([O-])CN(CC(=O)[O-])CC(=O)[O-].[Fe+2].[Fe+2].[Fe+2]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
ALOX15 P16050 2/20 0.52
MAPT P10636 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CA4 P22748 3/20 0.41
CASP1 P29466 1/20 0.37
FFAR3 O14843 2/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
EYA2 O00167 1/20 0.33
APP P05067 1/20 0.33
ACE P12821 1/20 0.33
LMNA P02545 1/20 0.32
CHRM2 P08172 1/20 0.32
ADRA2A P08913 1/20 0.32
TSHR P16473 1/20 0.32
DRD1 P21728 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitrilotriacetic Acid SCHEMBL9624643 0.97 KDM4E (0.50) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL30150827 0.97 KDM4E (0.50) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL9625156 0.97 KDM4E (0.50) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL11309540 0.93 KDM4E (0.52) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL1284701 0.93 KDM4E (0.59) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL23358712 0.93 KDM4E (0.52) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL1684921 0.93 KDM4E (0.52) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL2810628 0.93 KDM4E (0.52) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL1535541 0.93 KDM4E (0.52) KDM4EALOX15MAPTSMN1; SMN2CA4
Nitrilotriacetic Acid SCHEMBL11684108 0.93 KDM4E (0.52) KDM4EALOX15MAPTSMN1; SMN2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114833491-B Copper surface selective organic soldering flux and use method thereof 广东哈福技术股份有限公司 2024-04-30 CN claimed
CN-115312704-A Preparation method and application of material containing rich oxygen sites for modifying metal zinc negative electrode 浙江理工大学 2022-11-08 CN claimed
CN-114833491-A Copper surface selective organic solderability preservative and use method thereof 广东哈福科技有限公司 2022-08-02 CN claimed
CN-112457895-B Sulfur precipitator, desulfurization system and application thereof 中国石油化工集团有限公司 2021-07-09 CN claimed
CN-112457895-A Sulfur precipitator, desulfurization system and application thereof 中国石油化工集团有限公司 2021-03-09 CN claimed
CN-111257549-A Kit and method for detecting unsaturated iron binding force in serum 深圳迈瑞生物医疗电子股份有限公司 2020-06-09 CN claimed
CN-110922448-A Phosphorylated peptide enrichment device and method 谱度众合(武汉)生命科技有限公司 2020-03-27 CN claimed
US-4871520-A Process and composition for H2 S removal SHELL OIL COMPANY (US) 1989-10-03 US claimed
US-4859436-A H2 S removal process and composition SHELL OIL COMPANY (US) 1989-08-22 US claimed
CN-114833491-B Copper surface selective organic soldering flux and use method thereof 广东哈福技术股份有限公司 2024-04-30 CN disclosed
CN-114833491-B Copper surface selective organic soldering flux and use method thereof 广东哈福技术股份有限公司 2024-04-30 CN disclosed
CN-117042811-A Composition for cancer imaging 安斯泰来制药株式会社 2023-11-10 CN disclosed
US-20230255982-A1 METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF Reata Pharmaceuticals Holdings, LLC (US) 2023-08-17 US disclosed
CN-116286368-A Desulfurizing bacteria preservative 江西永丰博源实业有限公司 2023-06-23 CN disclosed
US-4859436-A H2 S removal process and composition SHELL OIL COMPANY (US) 1989-08-22 US disclosed
US-4664902-A Recovery of sulfur from a solid sulfur-containing solution of solubilized iron chelate of nitrilotriacetic acid SHELL OIL COMPANY (US) 1987-05-12 US disclosed
EP-0066309-B1 SULPHUR RECOVERY PROCESS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1985-03-27 EP disclosed
US-4363215-A CATALYTIC OXIDATION WITH HYDROGEN PEROXIDE PACIFIC GAS AND ELECTRIC COMPANY (US) 1982-12-14 US disclosed
EP-0066309-A1 Sulphur recovery process SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1982-12-08 EP disclosed
US-4348368-A Method of removing hydrogen sulfide from gases SHELL OIL COMPANY (US) 1982-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255982-A1 METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF CYP17A1, HSD11B2, HSD11B1 KDM4E 1007/4885ALOX15 27/4885MAPT 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.